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ABSTRACT
Objective Clinical Cancer Decision Tools (CCDTs) aim to 
alert general practitioners (GPs) to signs and symptoms 
of cancer, supporting prompt investigation and onward 
referral. CCDTs are available in primary care in the UK but 
are not widely utilised. Qualitative research has highlighted 
the complexities and mechanisms surrounding their 
implementation and use; this has focused on specific 
cancer types, formats, systems or settings. This study 
aims to synthesise qualitative data of GPs’ attitudes to 
and experience with a range of CCDTs to gain better 
understanding of the factors shaping their implementation 
and use.
Design A systematic search of the published (MEDLINE, 
CINAHL, Web of Science and EMBASE) and grey 
literature (July 2020). Following screening, selection and 
assessment of suitability, the data were analysed and 
synthesised using normalisation process theory.
Results Six studies (2011 to 2019), exploring the views 
of GPs were included for analysis. Studies focused on the 
use of several different types of CCDTs (Risk Assessment 
Tools (RAT) or electronic version of RAT (eRAT), QCancer 
and the 7- point checklist). GPs agreed CCDTs were 
useful to increase awareness of signs and symptoms of 
undiagnosed cancer. They had concerns about the impact 
on trust in their own clinical acumen, whether secondary 
care clinicians would consider referrals generated by 
CCDT as valid and whether integration of the CCDTs within 
existing systems was achievable.
Conclusions CCDTs might be a helpful adjunct to clinical 
work in primary care, but without careful development to 
legitimise their use GPs are likely to give precedence to 
clinical acumen and gut instinct. Stakeholder consultation 
with secondary care clinicians and consideration of 
how the CCDTs fit into a GP consultation are crucial to 
successful uptake. The role and responsibilities of a GP 
as a clinician, gatekeeper, health promoter and resource 
manager affect the interaction with and implementation of 
innovations such as CCDTs.
INTRODUCTION
Cancer survival in the UK is below that of 
European counterparts.1 One factor leading 
to poor outcome is the stage of cancer at diag-
nosis, a later stage at diagnosis makes optimum 
treatment more difficult. An ambition of The 
National Health Service (NHS) Long- Term 
Plan is to diagnose 75% of cancers at stage 1 or 
2 by 2028.2 Improvements in rates of smoking 
and obesity aim to reduce the lifetime risk of 
developing cancer and, improving uptake of 
screening aims to diagnose presymptomatic 
cancers. Improving early cancer diagnosis 
is one of the quality improvement tenets of 
the NHS England general practitioner (GP) 
Contract 2020/2021 and suggested areas for 
review include referral practice and use of 
Clinical Cancer Decision Tools (CCDTs).3
CCDTs are intended to alert GPs to suspi-
cious early signs and symptoms of an undiag-
nosed cancer. A number of CCDTs have been 
developed for use in primary care in England 
over the past 15 years to help GPs consider 
decisions about onward referral for investi-
gation or specialist assessment. QCancer is 
embedded in the Egton Medical Information 
System (EMIS) web electronic patient record 
system used by GPs in England as well as 
being available online ( www. qcancer. org). A 
Risk Assessment Tool (RAT), based on case 
control cohort studies, presented in a paper 
or mouse- mat form were sent to English GP 
practices in 2012. The two (QCancer and 
eRAT) were incorporated into GP software 
systems in 2013 and called ‘electronic cancer 
decision support tools for cancer’. These 
support tools were evaluated as part of a 
Cancer Research UK and MacMillan study.4 
The 7- point checklist (7PCL) is a validated 
diagnostic aid integrated into EMIS for assess-
ment of pigmented skin lesions.5 6
Despite efforts to assess and establish 
evidence for the use of CCDTs, findings from 
a UK- wide survey of GPs on CCDTs7 8 suggest 
that, of those practices with access to an elec-
tronic version of CCDTs, only a third have 
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clinical record systems. The survey responses suggest that 
‘levels of tool uptake are relatively low’.1 A recent system-
atic review9 of CCDTs to investigate whether they improve 
diagnostic decision making for cancer in primary care 
demonstrates their potential but note that effective imple-
mentation is still elusive.
Drawing on normalisation process theory (NPT), 
this study explores factors shaping the implementation 
and use of CCDTs in primary care. NPT is a framework 
designed to contextualise, understand and evaluate ‘the 
processes (implementation) by which new health technol-
ogies and other complex interventions are routinely oper-
ationalised in everyday work (embedding) and sustained 
in practice (integration)’.10 NPT provides a set of concep-
tual tools to aid understanding of this dynamic process. 
It considers four theoretical constructs: (1) coherence, 
(2) cognitive participation, (3) collective action and (4) 
reflexive monitoring (4–6).
Aim
This study aims to synthesise qualitative research on 
GPs’ attitudes to, and experiences of CCDTs. Drawing 
on a framework synthesis approach, it aims to provide a 
comprehensive analysis of factors shaping the implemen-
tation and use of CCDTs informed by NPT (6).
METHODS
Data sources and search strategy
A systematic electronic literature search from inception 
to July 2020 in MEDLINE, CINAHL, Web of Science and 
EMBASE databases was undertaken. A comprehensive 
predefined search strategy was developed by PTB using 
the SPICE (Setting Population Intervention Compar-
ison Evaluation11 box 1) approach. No publication type, 
language or date limits were applied to the searches. PTB 
carried out online searches via Google for grey literature 
using combinations of the terms from the electronic 
database searches. Email contact was made with two 
authors to establish that multiple publications were 
from the same study and another author was contacted 
to obtain a copy of a PhD thesis. Manual searches were 
undertaken by reviewing the reference lists of relevant 
identified literature from the database search results.
An example of the search strategy for EMBASE can be 
found in online supplemental material.
Selection criteria
Studies were included if they reported qualitative analysis 
(including qualitative aspects of mixed- methods studies) 
of GP’s participation and engagement with CCDTs. 
Studies which used face- to- face or telephone interviews, 
questionnaires, focus groups or direct observation were 
eligible. CCDTs were defined as any tool (digital, paper, 
electronic) used within a consultation which provided an 
outcome measure such as a percentage risk or a recom-
mendation to the doctor to consider an underlying cancer 
diagnosis as the cause for a patient’s signs or symptoms.
PTB and NH independently screened titles, abstracts 
and full articles using the inclusion criteria. Any differ-
ences in selections of full texts for inclusion were 
discussed until agreement on inclusion or exclusion was 
reached (full- text exclusions with reasons is available on 
request). An independent reviewer was available, this was 
not required.
Data extraction
For each article, all text from ‘Results/Findings’ and 
‘Discussion’ were extracted and imported into NVivo 
V.11 software (NVivo Qualitative data analysis Software; 
QSR International, V.11, 2016). Study characteristics were 
extracted into a spreadsheet to explore potential associa-
tions between specific themes and studies.
Critical appraisal
All included studies were critically appraised by PTB 
and NH using the Critical Appraisal Skills Programme 
checklist (CASP) for qualitative research.12 Any discrep-
ancies were resolved through discussion, until consensus 
was reached. The studies were not excluded or weighted 
based on the quality of reporting or any hierarchy of qual-
itative evidence.13
Data synthesis
Following familiarisation with the selected studies, PTB 
and NH developed a thematic framework to apply to the 
studies. The data were coded and charted line by line by 
PTB and NH. Themes and interpretation were discussed 
and refined with GM and mapped onto the NPT frame-
work.14 This work was aided by use of the adapted domain 
questions in table 1. The final analysis was discussed and 
validated by all authors.
Patient and public involvement
Patients and the public were not involved in the review.
Box 1 SPICE criteria
Setting
General practice/primary care in National Health Service /Western type 
public health carehealthcare system (primary care gatekeeper)
Population.
General practitioners/primary care doctors/family doctors.
Intervention
Cancer Clinical Decision Tools—paper, electronic, desktop, mouse- 
map, electronic decision aid/system.
Comparison
Normal practice/no comparator.
Other form of risk assessment.
Evaluation
Qualitative—face- to- face interviews, telephone interviews, question-
naires, focus groups, direct observation.
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RESULTS
The Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses diagram (figure 1) shows the results 
of the searches. Five published peer- reviewed articles, 
two reports and one PhD thesis were eligible for anal-
ysis.4 8 15–20 Two of the published papers came from the 
same study these have been considered as one dataset.18 19 
Another of the published articles and one of the reports 
were based on the same study data.16 17 The studies were 
published between 2011 and 2019.
Characteristics of included studies
The studies were heterogeneous in design, CCDT used 
and analysis. One study was from Australia8 and the others 
were from the UK.4 15–20 Data from 107 GPs is included in 
the selected studies (table 2).
The characteristics of the CCDTs assessed in the studies 
are summarised in table 3. These included RAT/eRAT,18 19 
QCancer8 two studies used both of these4 15 and one used 
the 7PCL20 (table 4). RAT/eRAT are CCDTs based on the 
results of population- based case- control studies, QCancer 
is based on statistically validated cohort studies, and the 
7PCL is a check box CCDT intended to be used as a 
support to GP decision making about referral for mela-
noma.20 7PCL is part of National Institute for Health 
and Care Excellence (NICE) recommendations for 
the assessment of pigmented lesions in Primary Care.21 
The CCDTs were presented to the clinician in different 
formats; including mouse mats, checklists and integrated 
computer prompts.
Table 1 Domains of NPT in relation to CCDT
NPT domains Questions
Coherence
(Meaning and sense making 
of participants)
How they make sense of 
the work of implementation 
and integration in order 
to promote/inhibit routine 
embedding of a practice.
Is the CCDT easy to describe?
Do GPs understand what the CCDT is?
Do GPs understand how the CCDT should be implemented?
Is the CCDT clearly distinct from other practices?
Do GPs express understanding of how the CCDT is distinct from other practices?
Does the CCDT have a clear purpose for GPs/patients?
Do GPs report a shared understanding of the purpose/benefit/value of the CCDT?
What benefits do GPS feel the CCDT will bring and to whom? (GPs/patients)?
Are these benefits valued by GPs?
Does the CCDT fit with the overall goals and activity of the organisation (practice/NHS)




Process and work go 
through to enrol individuals 
to engage with new practice
Do GPs think the CCDT a good idea—‘buy in’?
Do GPs see the point of the CCDT easily?
Are GPs willing to drive implementation?
Are GPs able to/willing to sustain involvement?
Do GPs feel is it ‘right’/legitimate they are involved?
Do GPs feel using CCDTs is a legitimate part of their role?
Collective action
(The work participants 
(individuals and 
organisations) do to make 
the intervention function)
How they enact it
What effect does the CCDT have on the work of GPs (how the CCDT affects the consultation)?
Does the CCDT promote or impede GPs work?
How compatible is the CCDT with existing work practices?
Does it make work easier?
How does it affect their roles/responsibilities/training needs?
Do GPs require extensive training before they can use the CCDT?
Is there organisational support for the CCDT?
Is there confidence in the new practice when they are using/enacting it?
What impact does the CCDT have on division of labour, resources, power and responsibility 
between professional groups?
Is there confidence in the new practice when they are using/enacting it?
Reflexive monitoring
(Participants reflect on or 
appraise the intervention)
How they appraise its 
effects——informal 
and formal appraisal of 
new practice to assess 
its advantages and 
disadvantages
How do GPs perceive the CCDT once it has been in use for a while?
Is the CCDT perceived as advantageous for patients or staff?
Are effects on them and their work clear?
How do they judge this?
Is it clear what effects the CCDT has had?
What are the effects on GPs and their work?
How do GPs appraise/evaluate this?
Can GPs contribute feedback about the CCDT once it is in use?
How are benefits or problems identified or measured?
Can the CCDT be adapted or improved on the basis of experience?
Has its use been altered while in use?
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One study asked GPs to participate in actor simulated 
cases using QCancer, followed by an interview exploring 
their experience.8 The other studies interviewed GPs after 
using the CCDTs in normal practice for a period of time. 
Two of these collected data via semistructured telephone 
interviews,4 16 17 one undertook face- to- face interviews,8 
another convened a focus group15 and one gathered data 
via a mix of face- to- face and telephone interviews.20 The 
interviews with GPs were conducted at variable time inter-
vals after using the CCDTs ranged from immediately to 
months later.
All studies used the framework method to analyse 
data. Underpinning theoretical frameworks included 
The normalisation process model (an earlier version of 
NPT),16 17 the Consolidated Framework for Implementa-
tion Research and Risk Communication Framework.15 20 
The remaining studies developed their own inductive 
coding framework.4 8 18 19
In the Australian study,8 there was a US$300 incen-
tive for participants. Practices were given some financial 
support via the Cancer Networks for participation in 
another study.18 19 These financial reward for participa-
tion were neither discussed in terms of its impact on the 
participants’ engagement nor their responses to inter-
view questions.
Quality assessment
Independent CASP assessment of all included studies, 
by PTB and NH demonstrated they were of high quality 
(available as online supplemental material). One omis-
sion from all studies was an exploration of the role of the 
interviewer in relation to the interviewee and any impact 
this could have on the data (reflexivity).22 This failure 
reflects on potential bias of the study and its conclusions.12
Synthesis
The synthesis focuses on; the CCDT, the role of the 
doctor, the consultation, the impact on cancer investiga-
tion and referrals, and the implications on and influence 
of secondary care cancer services.
Selected quotes from studies add richness to the frame-
work synthesis. They illustrate the themes and how they 
map onto the NPT domains. Where available demo-
graphic information about the source of the quote and 
the CCDT that the participant discussed is provided 
(table 4).
Coherence: the impact of CCDT on the role of the GP
Coherence refers to how participants make sense of an 
intervention.18 The data suggest that how GPs understand 
and make sense of CCDTs is inextricably linked to the 
perceptions of their role as a GP and how this is impacted 
by their use.
Communicating, sharing and understanding risk
A key result was that GPs were expected to communicate 
the pros and cons of a course of action, investigation, 
treatment and the likelihood of signs and/or symptoms 
present because of an undiagnosed cancer. This was influ-
enced by the potential reaction from patients. Different 
levels of comfort were experienced when using CCDTs 
within consultations8 15 because of the perceived impact 
of the information on the patient, how it was communi-
cated and what reaction that might elicit.
Some GPs had concerns that using the CCDT would 
increase patient anxiety so did not share the cancer 
risk figures, even keeping risk figures hidden from the 
patient’s view, or feeling that using the risk percentages 
in discussion with the patient would be challenging.4 8 
Others were comfortable using the CCDT to reassure 
patients.15 20
There was a lack of understanding about the intended 
role of the CCDT or how to use the results that it gener-
ated.4 15–17 This misunderstanding may reflect poor 
knowledge of how to interpret the results generated 
from a CCDT. Understanding how the CCDT fits within 
the current cancer pathway, how the cancer risk figures 
were calculated, might improve confidence in the validity 
of using a CCDT.8 15–17 Integration into the consultation 
might be encouraged by such knowledge.
Collaboration and involvement with secondary care and existing 
guidelines
A common theme across studies was the reported need 
for the CCDT to be integrated within existing referral 
pathways and endorsed by secondary care.4 15–17 GPs 
worried that a change in referral patterns, as a result of 
its use, might not be well received by hospital specialty 
team with no knowledge of it. Some participants felt 
uneasy using the CCDT to make referral decisions as a 
consequence. Having secondary care doctors’ endorse-
ment of the CCDT appears to be an important aspect in 
promoting its routine use for GPs. Justification of referrals 
Figure 1 The PRISMA diagram. PRISMA, Preferred 
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for suspected cancer using the percentages generated by 
the CCDT would require some knowledge of the CCDT 
by secondary care.4 15–17
Participants in one study questioned the legitimacy 
of integration of a checklist in the clinical system which 
already existed within local pathways and on referral 
forms.16 Participants commented that using a CCDT to 
determine referral decisions potentially threatens the 
professional identity and clinical reputation of a GP 
possibly undermining their relationship to secondary 
care.
The ‘one size fits all’ approach to training
Use of the CCDT by GPs was determined by their involve-
ment in a research study,15–17 the training they had prior 
to using the CCDT and the support that they received 
while using the CCDT.
Training is essential in determining coherence.4 It 
affects how GPs understand the CCDT, what makes the 
CCDT distinct from other practices and how it may 
benefit both the doctor and patient. Any training should 
aim to demonstrate how the CCDT fits with the responsi-
bilities and role of the doctor as well as the overall goals of 
the NHS in terms of timely diagnosis of cancer.
Cognitive participation: elements determining GPs use of 
CCDT
Cognitive participation refers to the commitment and 
engagement with an intervention.18 Two influences on 
engagement with CCDTs were identified.
Clinical acumen vs protocol
Some participants commented on their discomfort using 
the CCDT to aid their decision making rather than it 
being an instruction that had to be obeyed. Other GPs 
made it clear that they did not want to have their clinical 
acumen challenged by a CCDT.4 8 15–17 19 20 Protocolisation 
was one of the most commonly discussed factors affecting 
implementation.4 8 15–17 19 20 GP responses suggest a reluc-
tance to be protocol driven in their decision making. 
This questions the perceived legitimacy of the use of 
CCDTs when GPs do not feel it ‘right’ that they should be 
used.18 19 Some GPs did overrule the outcomes generated 
by the CCDT if these were not consistent with their clin-
ical impression.4 8 15 20
The CCDT was used to back up ‘instinct’ and ignored 
if it did not.4 20 Despite this theme being a dominant 
one, there was little exploration in the studies of whether 
the CCDT was used by GPs to justify not taking further 
action in those with a low risk of symptoms being caused 
by cancer and only one interviewee was quoted alluding 
to this.8 This could be because of assumptions about the 
underlying research agenda of early recognition and diag-
nosis rather than an appreciation that CCDTs might actu-
ally contribute to a reduction in over- investigation and 
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The medicolegal implications of using a new CCDT
Medicolegal implications of using a CCDT to determine 
a referral were highlighted by two of the studies.16 17 20 
Uptake could be impeded if GPs felt there was a medico-
legal threat to their decision from patients who were later 
diagnosed with cancer after the CCDT had highlighted 
an increased risk, but a decision had been made not to 
investigate or refer.
Collective action: impact of the CCDT on the work of the GP
Collective action is the work individuals and organisations 
do to make an intervention work.23 The implementation 
and use of CCDTs within primary care can impact on the 
work of a GP in a number of ways.
Increasing awareness
GPs found the use of CCDTs in clinical practice as bene-
ficial. Using them increased their awareness of cancer 
symptoms. For some GPs, the CCDT acted as a reminder 
of suspicious signs and symptoms.4 8 15–19 This was consid-
ered important for trainees and GPs less experienced in 
dermatology in the case of the 7PCL.20 There was appre-
ciation that some patients may not otherwise have had 
such a prompt referral to cancer services. The use of the 
CCDT increased awareness, thus building confidence in 
NICE guidelines.4 16
Prompt fatigue
Prompt fatigue because of CCDT generated reminders 
was mentioned by several studies.4 16 17 The electronic 
interruptions impacted on the flow of the consultation. 
The prompts were regarded, in some studies, as a nuisance 
making work more difficult16 17 another commented on 
the usefulness of prompts for future consultations.20
Impact of IT integration
A major component of how easy it was for GPs to engage 
with the CCDT was software integration with existing clin-
ical systems. GPs commented on clunky working and lack 
of support to operate the CCDT within the existing IT 
system.4 15–17 One study highlighted that the explosion of 
decision aids in clinical systems means they are sometimes 
available, but the clinician is unaware of their existence.20
Integration into clinical IT system was an issue which 
had the potential to ‘make or break’ implementation. 
When participants encountered problems with using the 
CCDT it was sometimes met with frustration, some GPs 
chose to abandon use.4 Time as a resource
Time and capacity issues was one of the most commonly 
discussed factors shaping implementation4 15–20 and a 
frequent response to questions involving any assessment 
of healthcare technology implementation. Recognition 
of the benefits of using a CCDT was essential to justify 
the additional time required for its use. This impacts on 
Table 3 CCDTs used in studies
Name Cancer type Format Use and development
Risk Assessment Tool 
(RAT)
Lung, colorectal Desk based Quantifies risk of cancer in symptomatic 
primary care patients.
Consists of risk score for high- risk 
symptoms in isolation, for repeat 
presentation of the same symptom and in 
combination with one other symptom.
Positive predictive Values for symptoms 
of cancer, developed through series of 
population- based case and control studies 
in primary care setting.
Electronic RAT Lung (non- smokers), lung 
(smokers), colorectal
Electronic Electronic version of clinical decision Risk 
Assessment Tools described above.
QCancer Lung, colorectal, gastro- 
oesophageal, pancreatic, blood, 
renal, prostate and various others
Electronic QCancer algorithms can be used to 
calculate the percentage probability of 
having an undiagnosed cancer.
Developed using QResearch database in 
a series of prospective cohort studies, it 
incorporates a range of risk factors.
Electronic clinical decision 
support 7 Point Check List
Melanoma Electronic Electronic Clinical Decision Support for 
assessment of pigmented lesions.
Integrated into EMIS clinical system.
A validated diagnostic checklist of 7 
weighted features of a pigmented lesion.
A score of 3 or more is suspicious of a 
diagnosis of melanoma.
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Table 4 Table of quotes to illustrate the themes




‘Sometimes I hide it, just in case I cause an alarm, but 
I will start to cover it during the consultation if there 
is any risk, yes. It depends because, you know, some 
patients, if they’re anxious, when they see something 
like that, they become more anxious’
Male GP eRAT4
‘If someone was very worried and they scored zero 
then I might be able to say, ‘Look, this is a scoring 
system that’s been developed,’ and it might just aid 
reassurance. Equally, if I was worried…I might just say, 
‘Look, this is the scoring system, you’ve got quite a lot 
of points on this. It doesn’t mean it’s anything serious 
but it does mean we need to look into it more closely’’




secondary care and 
existing guidelines
‘My concern is that the tools are not known to the 
secondary or hospital setup. So, I referred some 
patients, and I am concerned they may not recognise 
my QCancer referral…So, when I am thinking, if they 
see the patients I referred using QCancer, they will 
ask—who is this? Is this a new doctor, a new GP?’
GP, QCancer15
‘There are criterion boxes often and very occasionally 
a patient doesn’t quite fit one of the boxes and you 
tend to worry…but I think if you can justify whether 
actually they’ve got 38% chance of colorectal cancer 




One size fits all approach 
to training
‘Finally, data certainly highlighted that GPs might 
decide to refer on the basis of a holistic approach 
and, as many respondents emphasized, the approach 
of the individual GP and his/her level of clinical 




‘Although the tool itself doesn’t look that bad on the 
training, in terms of the implementation and making 





Clinical acumen vs 
protocol
‘I don’t think you can ever protocolise….make a risk 
schedule that is better than…experience’
GP, RAT
18 19
‘Without the checklist I already know what to look for. 
I know that if it’s changed in size, if it’s irregular, that 
those are all serious…So I would have already gone 
through it anyway, with or without the (list) in front of 
me, so does it really matter? Probably not. It’s in my 
head like any other medical problem, I mean, I consult 
all day long’




‘Quite a few partners were worried about any medical 
legal implications with that…what would be the 
implications? That was probably a point that put 
people off, really’
GP, eRAT16 17
‘If that’s the NICE guidance and that’s in the CCG 
2- week wait form, if you’ve got a score of 4 and you 
don’t refer, I think the lawyers would say that you’re 
not following guidance and they could sue you’
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Domain Theme Quote Source
Increasing awareness ‘Normally I’d get a few investigations, get the results 
back and then based on that say do we need to do 
something, or I refer this on based on that. But I guess 
if I have a calculator saying it’s higher risk, it might 
prompt me to make a referral to a specialist a bit 
earlier’
Female GP 31 years 
old, QCancer
8
‘It probably made us more aware than NICE 
guidance…it’s probably made me more aware of 
symptoms which I may have not been as aware of in 
the past’
Male GP, eRAT4
Prompt fatigue ‘we have all sorts of prompts coming at …it gets a little 
bit distracting …you’re trying to sort out and you’ve 
got all these messages flashing up at you’
Male GP, QCancer
4
Impact of IT integration ‘I suppose the prompt of a photo to be added would 
be helpful if they need to look through it’
Male GP 40 years old, 
7PCL20
‘There was a problem of accessing the tools as they 
are not integrated in our IT system. It was not easy 
downloading or googling the tools during patient 
consultation’
GP, QCacner15
‘so much hassle…we had to spend so much time…
trying to install it in every single desktop… couldn’t do 
it. I just gave up’
Male GP, eRAT4
Time as a resource ‘if it’s actually going to make life easier…is it going 
to improve care for the patient? Or is it …time really 
spent in filling up proformas?’
GP, RAT
18 19
‘I thought it was going to be time consuming using 
the tool. But…that will only be the case in the short 
term…it will be time saving in the long term, as the 
consultation, the assessments, investigations and 






‘there is a potential for using the tools for screening….
They could also be modified for asymptomatic 
patients’
GP, QCancer15
‘Your chest X- ray is perfectly normal. Your cough 
settles…I still have to try and convince you to stop 
smoking, to exercise, to lose weight…it should be 
used as a relationship tool’
Female GP 50 years 
old, QCancer8
Investigation and referral 
patterns
‘we were thinking that using the tools in consultation 
could result in unnecessary…over- referrals…I don’t 
think there will be over- referrals’
GP, QCancer
15
‘I think our referral thresholds for lower GI have 
definitely gone down’
Cancer Lead GP, RAT18 
19
Think Cancer ‘Yes, I must admit ovarian didn’t come so high up…
This really said hey, consider ovarian as well”
Male GP 46 QCancer8
‘If I had a patient with a vague set of symptoms 
then finding and using the tool showed that it was 
an amber…I might have followed up the patient in a 
different way…I’d like to see you again, just to see 
how these symptoms are, um, rather than leaving it to 
the patient to contact us”
Cancer Lead GP, RAT18 
19
eRAT, electronic Risk Assessment Tool; GP, general practitioner; NICE, National Institute for Health and Care Excellence; 7PCL, 7- point 
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consultation, time required to train users and the addi-
tional effort to continue using the CCDT. Time is at a 
premium in general practice in the UK: the pressures 
of the 10 min appointment,24 to keep up to date and to 
attend training.
Participants reported that adjusting to new work prac-
tices and integrating new techniques could take addi-
tional time, attention and commitment. However, there 
was evidence of recognition that initial investment may 
deliver improved patient care.15
Reflexive monitoring: GPs reflections on using a new 
technique
Reflexive monitoring is the appraisal work that is carried 
out by individuals utilising the CCDT.18
Unintended consequences
Despite not being an aim of CCDTs, it was recognised that 
they could be valuable to identify at risk patients or those 
suitable for screening.8 15 18 19 In terms of the NPT frame-
work, this highlights how the use of a complex interven-
tion is adapted, based on every day clinical practice and 
experience.
Another recognised unintended benefit of using the 
CCDT was in identifying patients’ modifiable lifestyle 
factors.8 15 This information was used in consultations 
to try and encourage behavioural change in relation 
to smoking, weight or alcohol consumption to reduce 
cancer risk and for general health promotion.
Investigation and referral patterns
It was acknowledged that the CCDT could reduce over-
investigation and over- referral to secondary care.4 15–20 
Conversely, others raised concerns that CCDT would 
increase the referral rates, but accepted that this could 
be auditable.15 18 19 A reduction in referrals to secondary 
care would have a positive impact on stretched secondary 
care services.
‘Think cancer’
All studies demonstrated that CCDTs prompted GPs to 
‘think cancer’4 8 15–20 and heightened awareness of rele-
vant signs and symptoms. CCDTs improved the speed 
of diagnosis and prompted investigations, referrals and 
counselling of patients. The data revealed that some GPs 
felt the CCDT elicited earlier review for patients with 
vague symptoms possibly being caused by an underlying 
cancer.18 19
DISCUSSION
This qualitative synthesis suggest that GPs recognise the 
need for awareness of the signs and symptoms of undi-
agnosed cancer and that the use of CDDTs can help 
to prompt early referral and diagnosis. As well as these 
intended benefits, GPs appreciate that CCDTs can be 
used in ways that benefit the patient doctor interaction. 
GPs used CCDTs to aid communication with patients 
about risks of cancer from suspicious as well as vague 
signs and symptoms and non- suspicious, to reassure 
anxious patients and to justify legitimate concerns. Using 
CCDTs in the context of worrying signs and symptoms 
provides GPs the opportunity to discuss preventative life-
style changes like weight loss and cessation of smoking 
which can reduce future risk of developing a cancer.
IT integration issues, interruptions, training and 
prompts were important factors in how the CCDT 
functioned in practice and crucial to how participants 
felt about committing to, and using, the CCDT within 
consultations.
For CCDTs to be implemented in routine practice, it is 
important they are thoughtfully developed with collabo-
ration and endorsement from secondary care to ensure 
compatibility with existing referral criteria. GPs need to 
be comfortable that the CCDT is another tool in their 
armamentarium and not seen as a replacement for their 
gut instinct, experience or factors related to relationships 
built up over time with patients.
In the field of CCDTs the understanding of risk and its 
communication needs to be tailored to GPs and patients 
in a simple, understandable way,25 26 particularly given the 
emotive and sensitive nature of suspected cancer and the 
emphasis on early diagnosis. The discussion of risk with 
patients and the emphasis on shared decision making 
(putting patients at the centre of any decisions ‘no deci-
sion about me without me’)27 within GP consultations is a 
key component of universal personalised care.2
CCDTs need to be considered clinically valuable, as easy 
as possible to use and integrate with existing pathways 
and practices,28 while causing minimal disruption to the 
consultation. Alert fatigue is a recognised consequence of 
prompts that are generated from the electronic patient 
record systems.29 Clinicians find that electronic prompts 
interrupt the flow of a consultation, are annoying and are 
often dismissed without full attention to their contents. 
This means reminders and alerts that could have a crit-
ical clinical impact on a patient are ignored. This is a real 
concern when the reason is to alert a clinician to an undi-
agnosed cancer.
GPs acknowledged that any CCDT, and the evidence 
behind them, need to be acceptable to specialists to 
whom they refer. GP compliance with guidelines is vari-
able,30 so discordance between a CCDT and local or 
national pathways needs to be avoided. Endorsement of 
CCDT by secondary care would reassure GPs that decision 
making about referrals was acceptable to both groups. 
In this context, closer cross- organisational collaboration 
and trust between healthcare professionals in primary 
and secondary care could be key to the successful imple-
mentation of CCDT.31 The Cochrane Review of Inter-
professional Collaboration32 concludes that to improve 
professional practice and healthcare outcomes, collab-
orative work is an area which deserves and is receiving 
increased academic interest.
The struggle between gut instinct (experience and 
knowledge of both the medicine and the patient with 
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and protocol is a recognised phenomenon which taps 
into the GPs’ professionalism (autonomy, accountability 
and responsibility).33 No new system should undermine 
or overrule clinical intuition but should accept that medi-
cine is an art, particularly in the emotively charged arena 
of cancer diagnosis. Mandating adherence to a partic-
ular set of protocols is fraught with barriers.34 A recent 
systematic review and meta- analysis found that the GP’s 
‘gut feeling’ was an important predictor of a cancer 
diagnosis.35
This is the first theoretically informed qualitative 
synthesis of the views and experiences of general prac-
titioners in relation to the implementation of Clinical 
Cancer Decision Tools (CCDTs) used within the rimary 
are consultation. The systematic and theory informed 
approach to synthesis allowed the identification of some 
generic and transferable issues relevant across a range of 
different CCDTs and contexts.
The small number of studies and data available for 
inclusion in this review limited detailed comparative anal-
ysis between CCDTs and contexts, and further work in 
this area may be beneficial. The quality and depth of the 
findings are limited by the quality of the studies included, 
and any bias of the original authors. Unfortunately the he 
small number of studies and data available for inclusion in 
this review limited the ability to carry out a more detailed 
comparative analysis between CCDTs and contexts, and 
further work in this area may be beneficial.
The studies are recent (2011 onwards) reflecting 
modern primary care practice but predominantly within 
the English NHS. The CCDTs evaluated are different: 
in format, in how the individual patient’s risk of cancer 
is calculated and their affinity with existing referral 
criteria. Nonetheless, this systematic and theory informed 
approach to synthesis identified some generic and trans-
ferable issues relevant across different CCDTs.
The ubiquitous electronic clinical decision aid takes 
many forms in primary care and this study reflects GPs’ 
experience from just those designed to improve recog-
nition of signs and symptoms that could be caused by 
an undiagnosed cancer. There are lessons to be learnt 
from the experience of successful implementation of 
electronic decision aids in other clinical domains such as 
cardiovascular disease.36
More evidence is needed that suspected cancer refer-
rals generated from the use of CCDTs lead to identifica-
tion of cancers at an earlier stage with subsequent impact 
on treatment outcomes. This evidence would further 
legitimise the use of CCDTs along with endorsement of 
their use by national guidance bodies for cancer pathways 
such as NICE in England.
CONCLUSIONS
Comprehensive cooperative working between primary 
and secondary care in planning, designing and imple-
menting CCDTs will benefit clinicians, patients, quality 
of healthcare and take account of scarce resources. 
Stakeholder consultation and involvement should be 
regarded as essential aspects of healthcare innovation 
and implementation.
The value that clinicians place on their clinical acumen 
and their desire for this to be recognised makes them 
wary to rely solely on protocol driven decision making. 
There will always be clinicians who find decision aids reas-
suring, those who find them helpful as an aide- memoire 
and those that find them a nuisance and will not use them 
at all. An ideal CCDT is one that does not undermine clin-
ical instincts but supports and enhances them.
CCDTs can be a helpful adjunct to clinical work in 
primary care, but without careful development legiti-
mising their use as well as consideration of training and 
IT integration with secondary care and IT systems, they 
may remain to be perceived as superfluous to clinical 
acumen and experience. Stakeholder consultation and 
involvement should be regarded as essential aspects of 
healthcare innovation and implementation.
This theoretically informed synthesis of existing quali-
tative work has helped to identify key themes and issues 
that influence the use and implementation of CCDTs 
across cancers, tools and settings. These insights can help 
to inform future development and implementation of 
CCDTs and fuller integration within policy and referral 
guidelines.
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